1	Title: RNA sequencing identifies human placental IL3RA as a potential predictor of adverse
2	cardiovascular outcomes in patients with severe preeclampsia
3	Authors: Omonigho Aisagbonhi, MD., Ph.D. ^{1,2*} Tony Bui, BS. ¹⁻³ , Hailee St. Louis, MD ¹ .,
4	Donald Pizzo, Ph.D ¹ ., Morgan Meads, BS. ¹⁻³ , Megan Mulholland, BS. ¹⁻³ , Robert Morey,
5	Ph.D ^{1,3} ., Celestine Magallanes, BS ⁴ , Leah Lamale-Smith, MD ⁴ , Louise C. Laurent, MD, Ph.D ⁴ .,
6	Marni B. Jacobs, Ph.D. ^{2,4} , Kathleen M. Fisch, Ph.D. ²⁻⁵ and Mariko Horii, MD ¹⁻³
7	Affiliations:
8	1. Department of Pathology, University of California, San Diego, La Jolla, California, USA
9	2. Center for Perinatal Discovery, University of California, San Diego, La Jolla, California,
10	USA
11	3. Sanford Consortium for Regenerative Medicine, University of California, San Diego, La
12	Jolla, California, USA
13	4. Department of Obstetrics, Gynecology and Reproductive Sciences, University of
14	California, San Diego, La Jolla, California, USA
15	5. Center for Computational Biology and Bioinformatics, University of California, San
16	Diego, La Jolla, California, USA
17	*Corresponding author:
18	Address: 9444 Medical Center Drive (1-200) La Jolla, CA 92037
19	E-mail: <u>oaisagbonhi@health.ucsd.edu</u>
20	Phone: 858-657-5464
21	Fax: 858-657-5495
22	Short title: IL3RA may predict adverse preeclampsia outcomes
23	Word count: 8216

24 Abstract

25	Background: Mortality from preeclampsia (PE) and PE-associated morbidities are 3-to 5-fold
26	higher in persons of African ancestry than in those of Asian and European ancestries. The
27	placenta is central to the etiology of PE. However, how and to what extent the placenta
28	contributes to worse PE outcomes in persons of African ancestry is yet to be fully elucidated.
29	Objective: We aimed to identify molecular pathways that are unique or enriched in placentas of
30	parturient persons of African ancestry with PE with severe features (sPE) compared to those of
31	Asian and European ancestry with sPE.
32	Study design: Bulk RNA sequencing was performed on 50 placentas from parturient persons
33	with sPE of African (n=9), Asian (n=18) and European (n=23) ancestries and 73 normotensive
34	controls of African (n=9), Asian (n=15) and European (n=49) ancestries.
35	Results: Metabolism, hormone regulation and hypoxia/angiogenesis genes, previously described
36	to be upregulated in PE, including: LEP, PAPPA2, INHA, FSTL3, FLT1, PHYHIP and ENG,
37	were upregulated in sPE across ancestries, with high expression of FSTL3 being additionally
38	associated with intrauterine growth restriction ($p = .0047$). Notably, the upregulation of, <i>FLT1</i> ,
39	LEP and PHYHIP was significantly higher in sPE placentas from parturient persons of African
40	versus Asian ancestry ($p = .0.35$, .020 and .012 respectively). Genes associated with allograft
41	rejection and adaptive immune response were upregulated in placentas from parturients of
42	African ancestry but not in those of Asian and European ancestries. Among the allograft
43	rejection/adaptive immune response genes, IL3RA was of particular interest because the patient
44	with the highest placental IL3RA level, a woman of African ancestry with IL3RA levels 4.5-fold
45	above the average for African ancestry parturients with sPE, developed postpartum
46	cardiomyopathy, and was the only patient out of 123, that developed this condition. Interestingly,

47	the sPE patients with the highest IL3RA levels among parturients of Asian and European
48	ancestries developed unexplained tachycardia peripartum, necessitating echocardiography in the
49	European ancestry patient. The association between elevated placental IL3RA levels and
50	unexplained tachycardia or peripartum cardiomyopathy was found to be significant in the 50 sPE
51	patients ($p = .0005$).
52	Conclusions: Placentas from parturients of African ancestry express higher levels of metabolism
53	(LEP) and hypoxia/angiogenesis (FLT1) genes, as well as allograft rejection/adaptive immune
54	response genes, including IL3RA. High placental expression of IL3RA may predict worse
55	maternal cardiovascular outcomes, including peripartum cardiomyopathy. Studies evaluating
56	placental IL3RA levels in peripartum cardiomyopathy cohorts are therefore warranted, as are

57 broader studies evaluating placental factors in maternal cardiovascular outcomes postpartum.

58

59 Introduction

Preeclampsia (PE) is a hypertensive disorder of pregnancy (HDP) that the WHO lists as one of the 5 major causes of maternal mortality worldwide¹. Pregnant and parturient persons of African ancestry have 1.5 to 2.5-times higher rates of PE²⁻⁵ and are 3 to 5-times more likely to die of PE than pregnant and parturient persons of Asian or European ancestry⁶⁻⁷. PE-associated morbidities, such as, stroke, pulmonary edema and heart failure, are also significantly higher in pregnant and parturient persons of African ancestry⁶⁻⁷.

66 Underlying comorbidities and lower socioeconomic status (SES) do not entirely explain the

67 higher PE rates and worse prognosis in persons of African ancestry. A population-based study of

68 718,604 Black and White pregnant and parturient persons from a California cohort of singleton

69 births found that, although White persons of higher SES had a lower risk of PE than White

70	persons of lower SES, higher SES did not attenuate PE risk in Black persons ⁸ . A review of the
71	records of 1,355 pregnant persons with HDP found similar rates of underlying chronic
72	hypertension in Black and White pregnant persons. However, among pregnant persons with HDP
73	without underlying chronic hypertension, Black persons were significantly more likely to be
74	diagnosed with PE than White persons ^{9.} In their retrospective cohort study of California births in
75	2007, Snowden et al ¹⁰ found that though obesity was a risk factor for PE and low birth weight in
76	White pregnant persons, obesity did not confer significantly increased PE risk in Black persons.
77	However, Black pregnant persons of normal weight had a higher risk of PE than White persons
78	of normal weight.
79	The placenta plays a central role in the pathology of PE, as PE only occurs in the context of
80	pregnancy, and delivery of the placenta is often curative ¹¹⁻¹³ . However, how the placenta
81	contributes to worse PE outcomes in pregnant and parturient persons of African ancestry, and
82	which specific placental injury pathways may be dysregulated in this population (and therefore
83	potential targets for therapy), are not well studied.
84	
85	Molecular and clinical data point to multiple pathways leading to PE. Using unsupervised
86	clustering of aggregate microarray datasets (first in 173 patient samples, including 77 with PE
87	and 96 controls, and later in a larger dataset of 330 samples, including 157 PE and 173 non-PE
88	samples), Leavey et al ¹⁴⁻¹⁵ identified 3 molecular clusters/subclasses of PE which they termed
89	maternal, canonical and immunologic. In the maternal PE group, infant birthweight and placental
90	weight were appropriate for gestational age, and placental histology and gene expression patterns
91	were not significantly different from normotensive controls. In the canonical PE group,
92	birthweight and placental weight were small for gestational age, placental histology showed

93	evidence of maternal vascular malperfusion, and genes associated with hormone regulation and
94	angiogenesis were overexpressed, with FSTL3 identified as the top differentially expressed gene.
95	In the immunologic PE group, birthweight and placental weight were small for gestational age,
96	placental histology showed massive/increased perivillous fibrin deposition, and genes associated
97	with immune and inflammatory responses were overexpressed.
98	
99	Recently, our group performed RNA sequencing on placentas from PE patients with evidence of
100	maternal vascular malperfusion and found trophoblast defects and activation of pathways
101	associated with hypoxia, inflammation and reduced cell proliferation in placentas with maternal
102	vascular malperfusion ¹⁶ , thus demonstrating that placental tissue RNA sequencing reflects
103	pathways associated with histologic evidence of placental injury in PE.
104	Therefore, we sought to elucidate the cellular and molecular underpinnings of the worse PE
105	outcomes in pregnant and parturient persons of African ancestry by performing bulk RNA
106	sequencing on placentas from persons affected by PE with severe features (sPE) and
107	normotensive controls of African ancestry compared to persons of Asian and European
108	ancestries. We hypothesized that molecular PE subclasses differ in placentas from parturient
109	persons of African ancestry versus those of Asian and European ancestries.
110	

111 Materials and Methods

112 Study cohort selection

113 The study was approved by University of California, San Diego (UCSD) institutional review

board, approval #181917. The study specimens were obtained from 2655 singleton parturitions at

115 UCSD-affiliated hospitals between January 2010 and November 2020. The patients whose

116	samples were collected gave written informed consent for accessing their electronic medical
117	records and collection of placental tissue. Demographic, clinical and placenta histology data
118	were collected in a REDCap-based obstetric registry. For each pregnancy, the clinical diagnosis
119	of preeclampsia with severe features (sPE) was adjudicated by 2 Board-Certified obstetricians.
120	Of the 2655 parturitions, 1003 for which the maternal ethnicity was recorded as Hispanic-other
121	were excluded, because Hispanic is a language group that can include people of diverse
122	ancestries, ranging from African (e.g. Afro-Cubans) to North and South Americans (e.g.
123	Mexicans and Brazilians), Asians (e.g. Spanish Filipinos) and Europeans (e.g. Spaniards).
124	Categorization as Hispanic-other thus provided insufficient information about ancestry and had
125	the potential to confound the study. 4 American Indian, 18 Native Hawaiian and 3 self-identified
126	multiracial without further ancestry delineation were excluded because the numbers of patients in
127	these categories were too few to gather generalizable information. There remained 142
128	parturitions with maternal African ancestry (self-identified as Black, African or African
129	American), 265 with Asian ancestry (self-identified as Asian) and 1220 with European ancestry
130	(self-identified as White, including Hispanic and non-Hispanic). Of these, RNA sequencing was
131	performed on 9 sPE and 9 normotensive controls of African ancestry, 18 sPE and 15
132	normotensive controls of Asian ancestry and 23 sPE and 49 normotensive controls of European
133	ancestry (Figure 1).
134	Obstetric Data

135 The demographic data collected included maternal ancestry, maternal age at delivery, gravidity,

136 parity, gestational age at delivery, fetal sex, birth weight, mode of delivery, documented sPE,

137 intrauterine growth restriction (IUGR), unexplained tachycardia, or peripartum cardiomyopathy.

138 RNA isolation from placental tissue, bulk RNA sequencing and analysis

139	Placenta disc villous tissue (avoiding the chorionic and basal plates) was collected and stored in
140	RNAlater (ThermoFisher). Total RNA was isolated from RNAlater-preserved specimens with
141	the mirVana RNA isolation kit using the manufacturer's Total RNA protocol (ThermoFisher)
142	and RNA concentration was measured using the QuBit RNA BR assay kit (ThermoFisher). RNA
143	integrity was evaluated using RNA 6000 Nano chip read by a 2100 Bioanalyzer (Agilent). All
144	samples had an RNA integrity number of >7.0. RNA sequencing libraries were prepared using
145	the TruSeq Stranded Total RNA Sample preparation kit with Ribo-Zero Gold (Illumina) at the
146	IGM Genomics Center, UCSD. The libraries were pooled and sequenced on the NovaSeq 6000
147	(Illumina) with PE100 to an average depth of 25,000,000 uniquely mapped reads. Quality control
148	was performed using FastQC (version 0.11.3). Reads were mapped to GRCh38.89 (Ensembl)
149	using STAR (version 2.7.9a) ¹⁷ on the Extreme Science and Engineering Discovery Environment
150	(XSEDE) ¹⁸ . The STAR parameters used were as follows: -runThreadN 24 -sjdbOverhang 99 -
151	genomeDir ref_ensembl_GRCh38_89/star_index -sjdbGTFtagExonParentGenegene_id -
152	sjdbGTFfile ref_ensembl_GRCh38_89/ Homo_sapiens.GRCh38.89.gtf -outSAMtype BAM
153	Unsorted SortedByCoordinateoutReadsUnmapped FastxquantMode Gene-Counts. Ensembl
154	genes with at least 10 counts in 25% of the samples were filtered for the analysis. Normalization
155	and the differential expression analysis (DEA) were performed using the R (version 4.2.1)
156	package DESeq2 (version 1.36.0) ¹⁹ . Data were accounted for batch effect, gestational age, and
157	gender, and adjusted p-value $< .05$ was considered differentially expressed. BiomaRt (version
158	2.42.1) was used to convert Ensembl gene identification numbers to Human Genome
159	Organization gene names ²⁰ . Gene set enrichment analysis (GSEA) was performed using the R
160	(version 4.2.1) package Fast Gene Set Enrichment Analysis (version 1.22.0). Gene ontology

analysis was performed using Enrichr²¹. Pathway analysis was performed using MsigDB

162 Hallmark gene set pathway analysis²². Venn diagrams were constructed using BioVenn²³.

163 *Immunohistochemistry*

Formalin-fixed paraffin-embedded placental tissue sections of 5 µm were stained with mouse 164 165 anti-CD123 (clone BR4MS; 1:100; Ventana) antibody using a manual staining method. Briefly, slides were incubated at 60°C for 1 hour, deparaffinized through standard xylene and alcohol 166 167 changes and hydrated in distilled water. Slides were pretreated in BioCare BORG decloaking 168 chamber at 125°C, 123psi. Slides were rinsed in TBS (BioCare Medical), peroxidase block (3% 169 hydrogen peroxide) was applied for 10 mins, after which slides were rinsed in TBS. Protein block with 0.5% casein (Vector) was performed for 10 mins, after which slides were rinsed in 170 171 TBS and then incubated with the CD123 antibody for 30 mins, rinsed in TBS and incubated in 172 post-primary reagent (rabbit anti-mouse Ig; Nvocastra) for 30 mins. Slides were again rinsed in TBS and then Novolink polymer (HRP-polumer-goat-anti-rabbit IG; Leica microsystems) was 173 applied for 30 mins. Slides were rinsed in TBS and then DAB reagent (DAKO) was applied. 174 Slides were rinsed in water, counterstained with hematoxylin, dehydrated, cleared with xylene 175 and then coverslip applied, per standard protocols. Immunohistochemistry was performed at San 176 Diego Pathologist Medical Group. 177

178 Immunohistochemistry quantification

179 CD123-stained placenta sections were evaluated to by a pathologist; cellular localization was

evaluated and scores were assigned based on intensity (no staining = 0, weak staining = 1,

moderate staining = 2 and strong staining = 3) and amount of staining (none = 0, focal = 1, $\frac{1}{2}$)

182 patchy = 2 and diffuse = 3). The total score comprised the sum of the intensity and amount

183 scores (lowest = 0 and highest = 6).

184 *Peripartum cardiomyopathy sub-study*

- 185 Electronic medical records of the 2655 singleton pregnancies with adjudicated diagnosis
- 186 (described in the study cohort section above) were searched using the term "cardiomyopathy"
- and 4 patients with bona fide peripartum cardiomyopathy (PPCM) in the index pregnancy were
- identified (Figure 6A).
- 189 Statistical analysis
- 190 Statistical analyses were performed using GraphPad Prism (version 9.4.1). The Mann-Whitney U
- 191 test was applied to all nonparametric data and student t test to all parametric data with continuous
- variables. The Pearson chi-square test was used for categorical variables. All statistical tests were
- 193 2-sided, with values < .05 considered statistically significant.

194

195 Results

196 Histopathologic analysis cohort

- 197 The histopathologic analysis cohort was comprised of 868 patients; 127 with sPE and 741
- 198 normotensive controls. Maternal age, gestational age at delivery, gravidity, parity, infant sex,
- infant birth weight and mode of delivery were evaluated in sPE patients African (n=15), Asian
- (n=23) and European (n=89) ancestries compared to normotensive controls of African (n=39),
- Asian (n=114) and European (n=588) ancestries. Gestational age at delivery and birth weight
- 202 were significantly less in sPE patients than in normotensive controls across ancestries
- 203 (Supplemental Table 1).

204

205 In patients with severe preeclampsia, African ancestry is associated with higher rates of

206 maternal vascular malperfusion and perivillous fibrin deposition

207	We analyzed the 868 placentas using previously defined histopathologic criteria ²⁴⁻²⁵ . We found
208	maternal vascular malperfusion and perivillous fibrin deposition occurred at significantly higher
209	rates in placentas from parturients of African ancestry with sPE compared to those of Asian or
210	European ancestry, suggesting worse placental injury in the African ancestry sPE group
211	(Supplemental Table 2).
212	
213	RNA sequencing patient demographics
214	Maternal age, gestational age at delivery, gravidity, parity, infant sex, infant birth weight and
215	mode of delivery were evaluated in sPE versus normotensive control patients of African, Asian
216	and European ancestries whose placenta samples were RNA sequenced. In comparison to
217	normotensive controls, infant birth weight was significantly lower in sPE parturitions across
218	ancestries while gestational age at delivery, gravidity and parity were significantly less in
219	African ancestry sPE parturitions (Supplemental Table 3).
220	Among the sPE patients, there was no significant difference in evaluated demographics -
221	maternal age, gestational age at delivery, gravidity, parity, infant sex, birth weight and mode of
222	delivery – across ancestries (Supplemental Table 4).
223	
224	Canonical preeclampsia genes and pathways are upregulated in placentas from patients of all
225	ancestries with sPE
226	We first performed differential expression analysis of sPE vs. normotensive controls within each
227	ancestry, and found 146 genes upregulated in African-sPE, 129 genes in Asian-sPE, and 637
228	genes in European-sPE placentas. 54 genes were upregulated in common in sPE placentas of all
229	3 ancestries (Figure 2A; Supplemental Tables 5-7). The relatively small number of differentially

230 expressed genes did not show enrichment of ontology terms using hypergeometric statistical tests. We therefore used our ranked gene list to perform gene set enrichment analysis (GSEA) to 231 look for enriched pathways in our dataset. The leading edge analysis identified the most highly 232 upregulated genes and pathways including those involved in metabolism (*LEP*, *HK2*), hormone 233 regulation (INHA, PAPPA2), and hypoxia/angiogenesis (FLT1, FSTL3, ENG, HTRA4), which 234 have been previously reported to be upregulated in PE^{14-15, 26-32} (Figure 2B-C; Supplemental 235 Tables 8-10). Based on review of prior publications showing evidence of associations with 236 preeclampsia, 9 of the leading edge genes we identified as upregulated in sPE patients across all 237 238 ancestries were chosen for further analyses (bolded in Figure 2A, arrows in Figure 2C). 239 African ancestry is associated with higher upregulation of PHYHIP and the canonical PE genes, 240 FLT1 and LEP 241 In evaluating the 9 selected genes upregulated in placentas of sPE patients vs. normotensive 242 controls of all ancestries, we noticed African ancestry sPE placentas showed higher fold-change 243 compared to fold-change from other ancestry groups (Table 1). 244 Therefore, we further investigated which of the 9 genes were specifically upregulated in sPE 245 246 placentas of African ancestry versus sPE placentas of Asian and European ancestries (excluding normotensive controls). We found FLT1, LEP and PHYHIP were more highly upregulated in 247 placentas from African ancestry sPE patients (Figure 3A; Supplemental Figure 1). 248 249 High placental upregulation of FSTL3 is associated with intrauterine growth restriction 250 We reviewed electronic medical records of all 123 study patients for intrauterine growth 251 restriction (IUGR), a known PE-associated pregnancy complication. IUGR was present in 28 of 252

253	123 patients (6 of 9 sPE African ancestry, 8 of 18 sPE Asian ancestry, 11 of 23 sPE European
254	ancestry, 0 of 9 normotensive African, 0 of 15 normotensive Asian and 3 of 49 normotensive
255	European patients). We evaluated IUGR in relation with DESeq2 normalized gene expression
256	levels of our 9 selected genes. We found that all 9 genes were significantly associated with
257	IUGR when sPE and normotensive IUGR patients were combined. However, only FSTL3, FLT1,
258	ENG and HTRA4 were associated with IUGR independently of preeclampsia; with FSTL3 being
259	the most highly upregulated gene (15.4-fold) in normotensive patients with IUGR (Figure 3B;
260	Supplemental Figure 2).
261	
262	Allograft rejection and adaptive immune response genes and pathways are selectively
263	upregulated in placentas from patients of African ancestry with sPE
264	In comparison to placentas from normotensive patients, 26 genes and 7 pathways were uniquely
265	upregulated in placentas from sPE patients of African ancestry and not in Asian or European
266	ancestry sPE placentas (Figure 4A-B). Allograft rejection and adaptive immune response
267	(interleukin-JAK-STAT signaling) pathways were among those uniquely upregulated in
268	placentas from African ancestry sPE patients. Interestingly, leading edge gene analysis identified
269	interleukin receptor, IL3RA, which is known for allograft rejection through interleukin
270	signaling ³³⁻³⁵ , to be selectively upregulated in placentas of sPE patients of African ancestry.
271	Therefore, IL3RA was chosen for further investigation in our study. We performed regression
272	analysis of IL3RA levels in placentas of sPE patients of African, Asian and European ancestries
273	delivered at various gestational ages and found IL3RA levels to be elevated in African ancestry
274	sPE placentas, regardless of gestational age at delivery (Supplemental Figure 3A). In African
275	ancestry parturients, individual placentas showed upregulation of both canonical (exemplified by

FLT1 and *LEP*) and allograft rejection/adaptive immune response genes (exemplified by *IL3RA*)
(Supplemental Figure 3B).

278

279 High placental upregulation of IL3RA is associated with unexplained tachycardia and

280 *peripartum cardiomyopathy*

281 We performed a detailed review of the electronic medical records of the sPE patients with the

highest placental *IL3RA* expression levels for their ancestry and found they developed either

283 peripartum cardiomyopathy (PPCM; African ancestry) or unexplained tachycardia (UET; Asian

and European ancestries) (Table 2; Figure 4C). Tachycardia in the absence of clinically

explained causes such as chorioamnionitis, urinary tract infection, viral infection, post-partum

hemorrhage/anemia, dehydration, sleep apnea and bulimia was classified as UET.

287 We thus searched for UET and PPCM in the medical records of all 50 sPE study patients and

found elevated *IL3RA* levels to be significantly associated with UET or PPCM (Fisher's exact

289 test p value .0005) (Table 3).

290

291 Placental syncytiotrophoblast CD123 expression by immunohistochemistry correlates with

292 placental IL3RA levels by RNA-seq

We evaluated the localization and expression pattern of CD123, the protein product of *IL3RA* by immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) sections from sPE patient placentas with the highest and lowest placental *IL3RA* levels for their ancestry (i.e. the 2 highest and 2 lowest *IL3RA*-expressing sPE placentas of each ancestry; N =12). There was variable CD123 expression in chorionic plate vessel endothelial cells, stem villous vessel endothelial cells, decidual vessel endothelial cells and syncytiotrophoblasts (Figure 5A-D). CD123

- expression in syncytiotrophoblasts correlated with *IL3RA* levels (simple linear regression p =
- 300 .0027), but expression in stem villous vessels did not (p = .1782) (Figure 5E-F).
- 301
- 302 Placental syncytiotrophoblast CD123 expression was detectable in only one of four peripartum
- 303 *cardiomyopathy patients*
- 304 We reviewed our database of 2655 singleton parturitions to identify patients who developed
- 305 peripartum cardiomyopathy (Figure 6A; Table 4).
- We subsequently evaluated placental CD123 expression in the 4 PPCM patients by
- 307 immunohistochemistry on FFPE tissue sections. Syncytiotrophoblast CD123 expression was
- 308 present only in the African ancestry PPCM patient (Figure 6B-E).

309

310 **Discussion**

Factors underlying increased PE risk and worse PE outcomes in African ancestry pregnancies 311 and parturitions are incompletely understood. In the current study, we evaluated placental gene 312 expression by RNA sequencing in patients with sPE of African, Asian and European ancestries 313 and found upregulation of canonical PE genes in sPE patients of all ancestries, with follistatin-314 like 3 (FSTL3) being associated with IUGR. FSTL3 is an activin antagonist that Mukherjee et al. 315 found to be involved in glucose and fat metabolism³⁶. In their unsupervised placental gene 316 expression profiling, Leavey et al^{14-15} found *FSTL3* to be the top gene associated with canonical 317 PE and IUGR. A 2021 study found elevated maternal serum levels of FSTL3 during pregnancy 318 to be predictive of fetal growth restriction³⁷. Our findings are in concordance with these studies. 319 320

321 Among the genes upregulated in PE across ancestries, we found higher expression of, Fmsrelated receptor tyrosine kinase 1 (FLT1), leptin (LEP) and phatonyl-CoA 2-hydroxylase 322 interacting protein (PHYHIP) in African ancestry sPE placentas. FLT1 is probably the most 323 324 widely recognized PE-associated gene, having been found to be upregulated in PE in multiple studies^{26-28, 38}. The ratio of soluble FLT-1 (sFlt-1) to placental growth factor (PIGF) has been 325 validated as a test to predict impending PE^{39} . *LEP* plays a major role in the regulation of energy 326 homeostasis and body weight⁴⁰. Elevated *LEP* has been previously described in preeclampsia in 327 multiple studies and leptin infusion in mice induces clinical characteristics of preeclampsia²⁹⁻³¹. 328 Longitudinal measurement of leptin/ceramide ratio outperformed sFlt-1/PIGF ratio in predicting 329 impending PE³¹. *PHYHIP* has been described to be involved in protein localization and has been 330 suggested to be involved in the development of Refsum disease, a neurologic disorder caused by 331 the toxic accumulation of phytanic acid in brain and peripheral neurons⁴¹. A few studies have 332 identified PHYHIP as one of the placenta genes associated with early-onset preeclampsia⁴²⁻⁴³. 333 Higher upregulation of FLT1, LEP and PHYHIP in placentas from pregnancies and parturitions 334 of maternal African ancestry may partly explain worse PE outcomes in this patient population. 335 336 We found genes and pathways involved in allograft rejection and adaptive immune responses to 337 be selectively upregulated in placentas from parturient persons of African ancestry with sPE and 338

not in those of Asian and European ancestries. Notably, individual placentas from patients of

340 African ancestry with sPE had upregulation of both canonical PE genes and allograft

- 341 rejection/adaptive immune response genes. This raises the possibility that rather than being
- 342 indicative of distinct PE etiologies (i.e. canonical versus immunologic), activation of allograft

rejection/adaptive immune response genes may be a marker of worse placental injury andharbinger of worse PE outcomes.

345

346	Among the allograft rejection and adaptive immune response genes, we found high placental
347	expression of interleukin 3 receptor alpha (IL3RA) to be associated with unexplained tachycardia
348	and peripartum cardiomyopathy in sPE patients. IL3RA is a cell surface receptor for IL3.
349	Binding of IL3 to IL3RA causes heterodimerization with the beta subunit, IL3RB, and
350	downstream JAK2-STAT5 signaling ⁴⁴ . IL5 and GM-CSF share the beta subunit with IL3 and can
351	activate signal transduction upon binding ⁴⁵ . High levels of IL3 and GM-CSF have been observed
352	in various models of heart failure. Vistnes et al. ⁴⁶ found IL3 and GM-CSF among the cytokines
353	increased upon inducing heart failure in a mouse cardiomyopathy model. IL3 caused allograft
354	fibrosis and chronic rejection of mouse heart transplants ³⁵ . IL3 impaired the cardioprotective
355	effects of endothelial cell-derived extracellular vesicles in a rat cardiac ischemia/reperfusion
356	model ⁴⁷ . In humans, Oren et al. ⁴⁸ found CRP, GM-CSF and IL3 to be significantly upregulated
357	in the first 12 hours of patients presenting to the emergency department with acute myocardial
358	infarctions.

359

360 We found placental endothelial cells and syncytiotrophoblasts express CD123, the protein

product of *IL3RA*, with syncytiotrophoblast CD123 expression being a better correlate of *IL3RA*

levels by RNA-sequencing. Syncytiotrophoblasts and decidual endothelial cells interact with the

maternal systemic circulation at the intervillous space and decidua respectively $^{49-50}$.

364 CD123/IL3RA localization to these cell types suggests *IL3RA* may exert its adverse

365 cardiovascular effects via interactions with the maternal systemic circulation and circulating

immune cells. In support of this theory is the finding by Anzai et al.⁵¹ that T-cell derived IL3 366 acted on IL3RA-expressing cardiac macrophages and fibroblasts to amplify autoimmune 367 inflammation in a mouse experimental myocarditis model. Furthermore, Pistulli et al⁵² found 368 369 accumulation of CD123+ dendritic cells in hearts of humans with acute myocarditis, and that dendritic cell accumulation caused adverse left ventricular remodeling in murine model of 370 experimental myocarditis. IL5, which shares the signal transducing beta subunit with IL3-371 IL3RA, is a contributor to the pathogenesis of eosinophilic myocarditis⁵³⁻⁵⁶. All together, the 372 upregulation of placental IL3RA in patients with sPE who develop unexplained tachycardia 373 and/or peripartum cardiomyopathy suggest that this marker may be a predictor and/or cause of 374 cardiac dysfunction, perhaps via interaction with circulating immune cells that then accumulate 375 in, and cause damage to, the heart. Studies of the crosstalk between syncytiotrophoblasts, 376 377 immune cells, and cardiomyocytes may yield further mechanistic insights into how the placenta may cause cardiovascular damage in susceptible patients. 378

379

The patient with the highest placental IL3RA expression level in our RNA sequenced cohort of 380 123 patients developed peripartum cardiomyopathy (PPCM). PPCM is a non-ischemic dilated 381 reduced ejection fraction (LVEF <45%) cardiomyopathy that typically presents towards the end 382 of pregnancy and in the months following delivery⁵⁷. The incidence of PPCM varies by ancestry, 383 being highest among people of African ancestry, with incidence rates reaching 1:100 in 384 Nigeria⁵⁸, and lowest among people of Asian ancestry, with rates as low as 1:20,000 in Japan⁵⁹. 385 Currently, the etiology of PPCM is thought to be multifactorial, with proposed causes that 386 include genetic predisposition in 15% of PPCM patients⁶⁰, vasculotoxicity of a 16kDa cleaved 387

388	prolactin fragment ⁶¹ , and inflammation ⁶² . There is an increased association of PPCM with
389	hypertensive disorders of pregnancy, with the association being strongest with sPE^{63} .
390	A 2018 study showed a higher prevalence of loss of function variants in cardiomyopathy genes
391	among patients with PE; with TTN mutations being most common ⁶⁴ . Interestingly, the African
392	ancestry sPE patient in our study who had the highest placental IL3RA level and developed
393	PPCM also had a c.83401T>C variant of uncertain significance (VUS) in TTN.
394	

395

We subsequently performed a review of our database of 2655 singleton parturitions and 396 identified 3 additional PPCM patients (4 total, including the African ancestry patient whose placenta had been RNA sequenced). Of the 4 patients, syncytiotrophoblast CD123 expression, 397 our surrogate marker for high placental IL3RA, was identified in 1 and absent in 3. A possible 398 explanation for this finding includes differing PPCM etiologies in the 4 patients. The 3 patients 399 without evidence of elevated IL3RA were older at delivery (age range 31-39 years), and 400 recovered cardiac function with normalization of their LVEF by 1-2 years postpartum. In 401 contrast, the patient with elevated *IL3RA* and *TTN* c.83401T>C was age 19 at delivery and still 402 has decreased LVEF and an implanted ICD 7 years postpartum. Though assessment for 403 404 cardiomyopathy-associated mutations were not performed in the 3 PPCM patients whose placentas were CD123-negative (due to lack of available preserved RNA), their recovery of 405 cardiac function/normalization of LVEF suggests decreased likelihood of underlying 406 407 cardiomyopathy-associated genetic mutations. In the IPAC (Investigations of Pregnancyassociated Cardiomyopathy) cohort, the presence of TTN truncating variants significantly 408 correlated with lower LVEF at 1 year follow up^{60} . 409

410	Using a genomics-first approach to evaluate for heart disease associated with titin-truncating
411	variants, dilated cardiomyopathy was identified in only 7.5% of people with TTN truncating
412	variants ⁶⁵ . As >90% of patients with TTN truncating variants do not develop dilated
413	cardiomyopathy or PPCM, our findings of elevated placental IL3RA in an African ancestry
414	PPCM patient with TTN c.83401T>C raises the possibility that high placental IL3RA precipitates
415	PPCM in genetically susceptible patients.
416	Our study was retrospective and limited by the small number of PPCM patients. Prospective
417	studies of placental IL3RA expression relative to cardiomyopathy-associated mutation status in

- 418 large PPCM cohorts are thus warranted.
- 419
- 420 Conclusion

421 We sought to identify placental factors that may explain worse PE outcomes in pregnancies and parturitions with maternal African ancestry and found higher upregulation of canonical PE genes 422 (FLT1, LEP and PHYHIP) and selective upregulation of allograft rejection/adaptive immune 423 response genes (IL3RA) in placentas from sPE patients of African ancestry versus sPE patients of 424 Asian and European ancestries. Furthermore, we found high placental IL3RA to be associated 425 with UET and PPCM in a subset of sPE patients. The higher expression of LEP, FLT1, PHYHIP 426 and IL3RA in placentas from patients of African ancestry with sPE likely contributes to the 427 worse PE outcomes in this patient population. As pregnancy is a semi-allogeneic state and HLA 428 diversity is higher in people of African ancestry⁶⁶, the possibility that the higher upregulation of 429 canonical PE genes, and selective upregulation of allograft rejection-associated genes in 430 pregnancies and parturitions with maternal African ancestry may be related to higher rates of 431 432 maternal-fetal HLA mismatches in this population, is an intriguing concept for future studies.

433

434 Acknowledgement

The authors are very grateful to all patients who consented and donated placental tissues to our
Perinatal Biorepository. We also thank Dr. Mana Parast for constructive critiques on the research
and manuscript.

438 Funding

439 This work was supported by funds from the University of California San Diego (UCSD)

440 Academic Senate grant #RG103465, the Health Resources and Services Administration of the

441 U.S Department of Health and Human Services Award Number D34HP31027 (Faculty

442 Development PIs Drs. JoAnn Trejo and Vivian Reznik), the UCSD Department of Obstetrics,

443 Gynecology, and Reproductive Sciences, the UCSD Department of Pathology and the UCSD

444 Stem Cell Program. Computational analysis was performed on the Extreme Science and

Engineering Discovery Environment (XSEDE) Expanse, which is supported by the National

446 Science Foundation grant #1548562 (allocation ID: MED210023). This research was partially

supported by the Altman Clinical & Translational Research Institute (ACTRI) at the University

of California, San Diego. The ACTRI is funded from awards issued by the National Center for

449 Advancing Translational Sciences, NIH UL1TR001442. This work includes data generated at the

450 UC San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased

451 with funding from a National Institutes of Health SIG grant (#S10 OD026929).

452 Author contributions

453 OA and MH designed the research; CM and MM recruited patients and collected clinical

454 information; MBJ and MM collected and managed database; LLS, and LCL were involved in

455 review of data within the obstetrics registry and adjudication of hypertensive disorders of

456	pre	egnancy; OA and HSL adjudicated adverse outcomes; TB performed RNA isolation; OA and								
457	DP performed immunohistochemistry analysis; OA, KMF, RM and MH performed RNAseq									
458	analysis; OA, MBJ, KMF, LCL and MH wrote the manuscript text. All the authors reviewed the									
459	fin	al version of the manuscript.								
460	Da	ta and code availability								
461	RN	JA-seq data have been deposited to the Gene Expression Omnibus database under the								
462	aco	cession number GSE234729 and GSE186257.								
463	Re	ferences								
464	1.	Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, Gulmezoglu AM,								
465		Temmerman M, Alkema L (2014). Global causes of maternal death: a WHO systemic								
466		analysis. Lancet Global Health; 2(6): e323-e333.								
467	2.	Breathett K, Muhlestein D, Foraker R, Gulati M (2014). Differences in preeclampsia rates								
468		between African American and Caucasian women: trends from the National Hospital								
469		discharge survey. J Womens Health (Larcmt). 23(11): 886-893.								
470	3.	Ghosh G, Grewal J, Mannisto T, Mendola P, Chen Z, Xie Y, Laughon SK (2014).								
471		Racial/ethnic differences in pregnancy-related hypertensive disease in nulliparous women.								
472		Ethn Dis. 24(3): 283-289.								
473	4.	Caughey AB, Stotland NE, Washington AE, Escobar GJ (2005). Maternal ethnicity, paternal								
474		ethnicity and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol 106(1):								
475		156-161.								
476	5.	Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA,								
477		Epling JW Jr, Kemper AR, Krist AH, Kurth AE, et al. (2017). Screening for preeclampsia:								
478		US preventive task force recommendation statement. JAMA 317(16):1661-1667.								

479	6.	Gyamfi-Bannerman C, Pandita A, Miller EC, Boehme AK, Wright JD, Siddiq Z, D'Alton
480		ME, Friedman AM (2020). Preeclampsia outcomes at delivery and race. J Matern Fetal
481		Neonatal Med 33(21): 3619-3626.
482	7.	Zhang M, Wan P, Ng K, Singh K, Cheng TH, Velickovic I, Dalloul M, Wlody D (2020).
483		Preeclampsia among African American pregnant women: an update on prevalence,
484		complications, etiology and biomarkers. Obstet Gynecol Surv 75(2): 111-120.
485	8.	Ross KM, Dunkel Schetter C, McLemore MR, Chambers BD, Paynter RA, Baer R, Feuer
486		SK, Flowers E, Karasek D, Pantell M (2019). Socioeconomic status, preeclampsia risk and
487		gestational length in black and white women. J Racial Ethn Health Disparities 6(6): 1182-
488		1191.
489	9.	Bryant AS, Seely EW, Cohen A, Lieberman E (2005). Patterns of pregnancy-related
490		hypertension in black and white women. Hypertens Pregnancy 24(3): 281-290.
491	10	. Snowden JM, Mission JF, Marshall NE, Quigley B, Main E, Gilbert WM, Chung JH,
492		Caughey AB (2016). The impact of maternal obesity and race/ethnicity on perinatal
493		outcomes: independent and joint effects. Obesity 7: 1590-1598.
494	11	. Soto-Wright V, Bernstein M, Goldstein DP, Berkowitz RS (1995). The changing clinical
495		presentation of complete molar pregnancy. Obstet Gynecol. 86(5):775e779.
496	12	. Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R (2010). Pre-eclampsia. Lancet.
497		376(9741):631e644.
498	13	. August P, Sibai BM. Preeclampsia: clinical features and diagnosis. In: Lockwood CJ, ed.
499		UpToDate. UpToDate, Inc; 2019.
500	14	. Leavey K, Bainbridge SA, Cox BJ (2015). Large scale aggregate microanalysis reveals three
501		distinct molecular subclasses of human preeclampsia. PLoS ONE 10(2): e0116508

- 502 15. Leavey K, Benton SJ, Grynspan D, Kingdom JC, Bainbridge SA, Cox BJ (2016).
- 503 Unsupervised placental gene expression profiling identifies clinically relevant subclasses of
- human preeclampsia. Hypertension 68: 137-147
- 16. Horii M, To C, Morey R, Jacobs MB, Li Y, Nelson KK, Meads M, Siegel BA, Pizzo D,
- Adami R, et al. (2023). Histopathologic and transcriptomic profiling identifies novel
- trophoblast defects in patients with preeclampsia and maternal vascular malperfusion. Mod
- 508 Pathol. 36(2): 100035
- 509 17. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M,
- 510 Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics.
- 511 29(1):15e21.
- 512 18. Towns J, Cockerill T, Dahan M, Foster I, Gaither K, Grimshaw A, Hazlewood V, Lathrop S,
- Lifka D, Peterson G, et al. (2014). XSEDE: accelerating scientific discovery. Comput Sci
 Eng. 16(5):62e74.
- 515 19. Love MI, Huber W, Anders S. (2014). Moderated estimation of fold change and dispersion
 516 for RNA-seq data with DESeq2. Genome Biol. 15(12):550.
- 517 20. Durinck S, Spellman PT, Birney E, Huber W. (2009). Mapping identifiers for the integration
- of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 4(8):1184e1191.
- 519 21. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S,
- Jenkins SL, Jagodnik KM, Lachmann A, et al. (2016). Enrichr: a comprehensive gene set
 enrichment analysis web server 2016 update. Nucleic Acids Res. 44(W1):W90eW97.
- 522 22. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. (2015). The
- 523 Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst.
- 524 23;1(6):417-425.

525	23. Hulsen T, de Vlieg J, Alkema W. (2008). BioVenn – a web application for the comparison
526	and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics
527	9 (1): 488.
528	24. Khong TY, Mooney EE, Ariel I, Balmus NCM, Boyd TK, Brundler MA, Derricott H, Evans
529	MJ, Faye-Petersen OM, Gillan JE, et al (2016). Sampling and definitions of placental lesions:
530	Amsterdam placental workshop group consensus statement. Arch Pathol Lab Med.
531	140(7):698e713.
532	25. Redline RW, Ravishankar S, Bagby CM, Saab ST, Zarei S (2021). Four major patterns of
533	placental injury: a stepwise guide for understanding and implementing the 2016 Amsterdam
534	consensus. Mod Pathol. 34(6):1074e1092.
535	26. Brew O, Sullivan MHF, Woodman A (2016). Comparison of normal and preeclamptic
536	placental gene expression: a systematic review with meta-analysis. PLoS ONE 11(8):
537	e0161504.
538	27. Kaartokallio T, Cervera A, Kyllonen A, Laivuori K, Kere J, Laivuori H (2015). Gene
539	expression profiling of preeclamptic placentae by RNA sequencing. Scientific reports 5:
540	14107.
541	28. Varkonyi T, Nagy B, Fule T, Tarca AL, Karaszi K, Schonleber J, Hupuczi P, Mihalik N,
542	Kovalsky I, Rigo J Jr, et al. (2011). Microarray profiling reveals that placental transcriptomes
543	of early-onset HELLP syndrome and preeclampsia are similar. Placenta. 32: S21-S29.
544	29. de Knegt VE, Hedley PL, Kanters JK, Thagaard IN, Krebs L, Christiansen M, Lausten-
545	Thomsen U (2021). The role of leptin in fetal growth during preeclampsia. Int. J. Mol. Sci.
546	22: 4569

- 30. Mellot E, Faulkner JL (2023). Mechanisms of leptin-induced endothelial dysfunction. Curr
 Opin Nephrol Hypertens. 32(2): 118-123.
- 549 31. Huang Q, Hao S, You J, Yao X, Li Z, Schilling J, Thyparambil S, Liao WL, Zhou X, Mo L,
- et al. (2021). Early pregnancy prediction of risk for preeclampsia using maternal blood
- leptin/ceramide ratio: discovery and confirmation. BMJ Open 11: e050963.
- 32. Wang Y, Lim R, Nie G. Htra4 may play a major role in inhibiting endothelial repair in
- 553 pregnancy complication preeclampsia (2019). Scientific Reports 9: 2728
- 33. Xu X, Huang H, Cai M, Qian Y, Han Y, Xiao L, Zhou W, Wang X, Shi B (2011). Serum
- hematopoietic growth factors as diagnostic can prognostic markers of acute renal allograft
- rejection: a potential role for serum stem cell factor. Cytokine. 56: 779-785.
- 557 34. Nocera A, Tagliamacco A, Ferrante A, Fontana I, Rolla D, De Palma R, Del Galdo F,
- 558 Ginevri F, Barocci S, Valente U (2005). Cytotoxic molecule mRNA expression in
- chronically rejected human kidney allografts. Transplant Proc. 37: 2476-2478.
- 560 35. Balam S, Schiechl-Brachner G, Buchtler S, Halbritter D, Schmidbauer K, Talke Y,
- 561 Neumayer S, Salewski J, Winter F, Karasuyama K, et al. (2019). IL-3 triggers chronic
- rejection of cardiac allografts by activation of infiltrating basophils. J Immunol. 202: 35143523.
- 36. Murkherjee A, Sidis Y, Mahan A, Raher MJ, Xia Y, Rosen EB, Bloch KD, Thomas MK,
- Schneyer AL (2007). FSTL3 deletion reveals roles for TGF-beta family ligands in glucose
 and fat homeostasis in adults. Proc Natl Acad Sci 104 (4): 1348-1353.
- 567 37. Gong S, Gaccioli F, Dopierala J, Sovio U, Cook E, Volders PJ, Martens L, Kirk PDW,
- 568 Richardson S, Smith GCS, Charnock-Jones DS (2021). The RNA landscape of the human
- placenta in health and disease. Nat Commun 12(1): 2639.

- 570 38. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP,
- 571 Sellke FW, Stillman IE, et al. (2003). Excess placental soluble fms-like tyrosine kinase 1
- 572 (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in
- 573 preeclampsia. J Clin Invest 111(5): 649-658.
- 39. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, Olovsson M,
- 575 Brennecke SP, Stephan H, Allegranza D, et al. (2016). Predictive value of the sFlt-1:PIGF
- ratio in women with suspected preeclampsia. N Engl J Med 374(1): 13-22.
- 40. Hamann A, Matthaei S (1996). Regulation of energy balance by leptin. Exp Clin Endocrinol
 Diabetes 104(4): 293-300.
- 41. Koh JT, Lee ZH, Ahn KY, Kim JK, Bae CS, Kim HH, Kee JH, Kim KK (2001).
- 580 Characterization of mouse brain-specific angiogenesis inhibitor 1 (BAI1) and phytonyl-CoA-
- alpha-hydroxylase-associated protein 1, a novel BAI1-binding protein. Brain Res Mol Brain
 Res 87(2): 223-237.
- 42. Blair JD, Yuen RKC, Lin BK, McFadden DE, von Dadelszen P, Robinson WP (2013).
- Widespread DNA hypomethylation at gene enhancer regions in placentas associated with
 early-onset preeclampsia. Mol Hum Reprod 19(10): 697-708.
- 43. Leavey K, Wilson SL, Bainbridge SA, Robinson WP, Cox BJ (2018). Epigenetic regulation
- of placental gene expression in transcriptional subtypes of preeclampsia. Clin Epigenetics10:28.
- 589 44. Broughton SE, Hercus TR, Nero TL, Kan WL, Barry EF, Dottore M, Cheung Tung Shing
- 590 KS, Morton CJ, Dhagat U, Hardy MP, et al (2018). A dual role for the N-terminal domain of
- the IL-3 receptor in cell signaling. Nat. Commun. 9: 386

- 45. Broughton SE, et al. (2012). The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand
 recognition to initiation of signaling. Immunol. Rev. 250: 277-302.
- 46. Vistnes M, Waehre A, Nygard S, Sjaastad I, Andersson KB, Husberg C, Christensen G
- 595 (2010). Circulating cytokine levels in mice with heart failure are etiology dependent. J Appl
- 596 Physiol. 108: 1357-1364.
- 47. Penna C, Femmino S, Tapparo M, Lopatina T, Espolin Fladmark K, Ravera F, Comita S,
- Alloatti G, Giusti I, Dolo V, et al. (2020). The inflammatory cytokine IL-3 hampers
- cardioprotection mediated by endothelial cell-derived extracellular vesicles possibly via their
- 600 protein cargo. Cells. 10:13. doi: 10.3390/cells10010013.
- 48. Oren H, Riza Erbay A, Balci M, Cehreli S (2007). Role of novel mediators of inflammation
- in left ventricular remodeling in patients with acute myocardial infarction: do they affectoutcome of patients? Angiology 58: 45-54.
- 49. Moffett A, Locke C (2006). Immunology of placentation in eutherian mammals. Nat. Rev.
 Immunol. 6: 584-594.
- 50. Aisagbonhi A, Morris GP (2022). Human leukocyte antigens in pregnancy and preeclampsia.
 Front Genet 13: 884275. doi: 10.3389/fgene.2022.884275.
- 51. Anzai A, Mindur JE, Halle L, Sano S, Choi JL, He S, McAlpine CS, Chan CT, Kahles F,
- Valet C, et al. (2019). Self-reactive CD4⁺ IL-3⁺ T cells amplify autoimmune inflammation in
 myocarditis by inciting monocyte chemotaxis.
- 52. Pistulli R, Andreas E, Konig S, Drobnik S, Kretzschmar D, Rohm I, Lichtnauer M,
- Heidecker B, Franz M, Mall G, et al. (2020). Characterization of dendritic cells in human and
- experimental myocarditis. ESC Heart Fail. 7: 2305-2317.

614	53. Yadavalli CS, Mishra A (2022). IL-5 overexpression induced blood eosinophilia associated
615	progression of cardiac abnormalities. Int J Basic Clin Immunol. 5: 1-7.

- 54. Hirasawa M, Ito Y, Shibata MA, Otsuki Y (2007). Mechanism of inflammation in murine
- 617 eosinophilic myocarditis produced by adoptive transfer with ovalbumin challenge. Int Arch
- 618 Allergy Immunol. 142: 28-39.
- 55. Song T, Jones DM, Homsi Y (2017). Therapeutic effect of anti-IL-5 on eosinophilic
- myocarditis with large pericardial effusion. BMJ Case Rep. 2017:bcr2016218992.
- 56. Desreumax P, Janin A, Dubucquoi S, Copin MC, Torpier G, Capron A, Capron M, Prin L
- 622 (1993). Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart
- 623 diseases. Blood. 82: 1553-1560.
- 57. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U (2020). Peripartum
- 625 cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 75(2): 207-221.
- 58. Isezuo SA, Abubakar SA (2007). Epidemiologic profile of peripartum cardiomyopathy in a
 tertiary care hospital. Ethn Dis 17: 228-233.
- 59. Kamiya CA, Kitakaze M, Hatsue IU, Nakatani S, Murohara T, Tomoike H, Ikeda T (2011).
- Different characteristics of peripartum cardiomyopathy between patients complicated with
- and without hypertensive disorders results from the Japanese nationwide survey of
- 631 peripartum cardiomyopathy. Circ J 75: 1975-1981.
- 632 60. Ware JS, Li J, Mazaika MA, Yasso CM, DeSouza T, Cappola T, Tsai EJ, Hilfiker-Kleiner D,
- 633 Kamiya CA, Mazzarotto F, et al. (2016). Shared genetic predisposition in peripartum and
- dilated cardiomyopathies. N Engl J Med 374: 233-241.

635 61. Hilfiker-Kleiner D, Kaminski E, Podewski E, Bonda I, Schaefer A, Silwa K, For

- 636 Quint A, Landmesser U, Doerries C, et al. (2007). A cathespsin D-cleaved 16kDa form of
- 637 prolactin mediates postpartum cardiomyopathy. Cell 128(3): 589-600.
- 638 62. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R (2005). High prevalence of
- viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 193:
- 640 <u>363-365</u>.
- 641 63. Bello N, Rendon IS, Arany Z (2013). The relationship between preeclampsia and peripartum
- 642 cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 62: 1715-1723.
- 643 64. Gammill HS, Chettier R, Brewer A, Roberts JM, Shree R, Tsigas E, Ward K (2018).
- 644 Cardiomyopathy and preeclampsia: shared genetics? Circulation 138: 2359-2366.
- 645 65. Haggerty CM, Damrauer SM, Levin MG, Birtwell D, Carey DJ, Golden AM, Hartzel DN,
- 646 Hu Y, Judy R, Kelly MA, et al (2019). Genomics-first evaluation of heart disease associated
- 647 with titin-truncating variants. Circulation 140(1): 42-54.
- 648 66. Prugnolle F, Manica A, Charpentier M, Guegan JF, Guernier V, Balloux F (2005). Pathogen-
- driven selection and worldwide HLA class I diversity. Cur Biol 15(11): 1022-1027.
- 650

651 Tables

PAPPA2	4.42	.02	4.25	.0021	2.96	.00015
FLT-1	7.54	.0032	5.88	.0011	5.04	1.21E-06
ENG	4.09	.0047	3.06	.0095	2.66	2.48E-05
HTRA4	13.56	.0076	6.15	.027	4.96	7.49E-06
INHA	6.52	.0367	3.38	.0041	2.38	.00024
PHYHIP	6.69	.0094	2.53	NS	2.60	.00038

Table 1: Fold changes in select genes significantly upregulated in severe PE (versus 652

normotensive controls) per ancestry. p values represent adjusted p values calculated using 653 DESeq2.

654

655

Ancestry	IL3RA level	Fold greater than average PE levels for ancestry	Peripartum cardiac symptoms	Recurrent PE (Y/N)?
African	938.05	4.5	Cough, SOB, abdominal distension 5 months post-partum. Found to have dilated cardiomyopathy with 10% LVEF; diagnosed with peripartum cardiomyopathy	Y- severe PE with IUGR 6 years later
Asian	54.91	2.3	Unexplained tachycardia that self- resolved; did not require an echocardiogram.	Y – superimposed PE 2 years later
European	167.82	4.6	Tachycardia to 120s peripartum – required echocardiogram to exclude peripartum cardiomyopathy; echo showed mild LV diastolic dysfunction and mild pulmonary hypertension, but preserved EF; tachycardia eventually self-resolved	Unknown – had a subsequent pregnancy 1 year later, but no further records after 10w4d visit

Table 2: Peripartum cardiac symptoms and recurrent preeclampsia in the severe preeclampsia 656

with the highest placental IL3RA levels for their ancestry. Abbreviations: PE: preeclampsia, 657

SOB: shortness of breath, IUGR: intrauterine growth restriction, LVEF: left ventricular ejection 658

fraction, LV: left ventricle; EF: ejection fraction 659

PPCM/ unexplained tachycardia frequency in PE patients	IL3RA	PPCM or unexplained tachycardia	No PPCM or unexplained tachycardia
African sPE: 1/9 (11.1%) Asian sPE: 1/18 (5.5%) European	<i>IL3RA</i> 2-fold-fold greater than PE average for ancestry	African – 1 Asian – 1 European – 1 Total – 3	African – 0 Asian – 0 European – 0 Total – 0
sPE: 3/23 (13%)	<i>IL3RA</i> less than 2-fold of PE average for ancestry	African – 0 Asian – 0 European – 2 Total – 2	African – 8 Asian – 17 European – 20 Total – 45
Total: 5/50 (10%)	Fisher's exact test p-value .0005		

Table 3: Frequency of unexplained tachycardia or peripartum cardiomyopathy and their
relationship with *IL3RA* levels in parturitions complicated by preeclampsia with severe features
(sPE) per ancestry (N=50). Comparison placental *IL3RA* levels were set to 2-fold greater than
average of the levels in sPE patients per ancestry.

Ancestry/ Age	Smoking	BMI	GA	Preceding	PPCM presentation	Genetics
Language	history			diagnosis		

1	African	19	NS	45.09	26.6	sPE	Cough, SOB and abdominal distension 5 months postpartum. Found to have severe LV dilatation without LVH; LVEF 10%; developed LV thrombus. Was initially considered for transplant, but LVEF improved to 40% 2 years later; but then dropped to 27% again after another 2 years (post-second pregnancy) – currently has an ICD	<i>TTN</i> c.83401T>C VUS
2	Hispanic	34	NS	26.85	33.1	sPE	Developed tachycardia, SOB, hypoxia and pulmonary edema soon after completion of emergency C-section for severe PE. Found to have normal LV size but LVEF 10- 15%; improved to 28% 2 days later; then 48% 1 month later; fully (63%) 3 months later	Not performed
3	Hispanic	31	NS	31.83	36.4	sisPE	h/o poorly controlled DM2; found to have mildly decreased LVEF (49%) at 15w GA- followed by cardiology; C/S at 36w4d for sisPE; found to have moderate LV dilatation and LVEF 35-40% 3 months	Not performed

4 European	39	NS	21.28 34.5	sisPE with HELLP	postpartum; no subsequent records in our system SOB and O2 sats 80s 1 month postpartum. Found to have mild LV dilatation without LVH; LVEF 30-35%; improved to 48% 3 months later and fully (63%)	Not performed
					2 years later.	

Table 4: Clinical profile of the 4 patients with peripartum cardiomyopathy (PPCM) in our
database of 2655 singleton parturitions. Abbreviations: NS: never-smoker; BMI: body mass
index; GA: gestational age; sPE: preeclampsia with severe features; sisPE: superimposed
preeclampsia (i.e. preeclampsia with a history of underlying chronic hypertension) with severe
features; HELLP: hemolysis, elevated liver enzymes and low platelets; SOB: shortness of breath;
LV: left ventricle; LVH: left ventricular hypertrophy; LVEF: left ventricular ejection fraction;
implantable cardioverter defibrillator; DM2: type II diabetes mellitus; VUS: variant of

- 673 uncertain significance.
- 674

675 **Figure legends**

Figure 1: RNA sequencing study design. Abbreviations sPE: preeclampsia with severe features;

677 GA: gestational age

Figure 2: Genes and pathways upregulated in common in placentas from severe PE versus

normotensive patients of all ancestries. A. Genes upregulated in severe PE versus normotensive

680 placentas – genes in bold have been identified in multiple studies. B. Hallmark signaling

pathways upregulated in severe PE versus normotensive placentas. C. Heat map of top 50 genes

682 upregulated in severe preeclampsia versus normotensive controls. Arrows point to genes chosen

- 683 for further analysis in this study.
- Figure 3: A. DEseq2 normalized expression of FLT1, LEP and PHYHIP which are more highly
- 685 upregulated in placentas from African ancestry patients with severe preeclampsia versus Asian

- ancestry patients with severe preeclampsia. B. Evaluation of intrauterine growth restriction(IUGR) in relation to DESeq2 normalized gene expression.
- 688Figure 4: Genes and pathways uniquely upregulated in placentas from severe PE patients of
- 689 African ancestry and not in Asian or European ancestry severe PE patients. A. Genes uniquely
- 690 upregulated in placentas from severe PE patients of African ancestry IL3RA is bolded due to its
- 691 significance in this study. B. Hallmark signaling pathways uniquely upregulated in placentas
- from severe PE patients of African ancestry. C. Patients with the highest placental IL3RA levels
- 693 for their ancestry developed cardiac symptoms.
- Figure 5: CD123 localization in placenta sections; in placentas with CD123 expression, variable
- 695 expression was seen in chorionic plate vessels (A), stem villous vessels (B), decidual vessels (C)
- and syncytiotrophoblasts (D) (top panels are from a patient without PPCM; bottom panels are
- from the patient with PPCM). CD123 expression in syncytiotrophoblasts correlated better with
- 698 IL3RA levels than expression in stem villous vessels (E and F). Abbreviations: PPCM
- 699 peripartum cardiomyopathy; UET: unexplained tachycardia.
- Figure 6: Evaluating the relationship between placental CD123 expression and peripartum
- cardiomyopathy. A. Study design. CD123 immunohistochemical stains were performed on the
- 702 PPCM patients of African ancestry (B), European ancestry (C) and Hispanic language group (D-
- E). Only the African ancestry patient had detectable syncytiotrophoblast CD123 expression.







FIGURE 4







FIGURE 5





A. Study design



cardiomyopathy rates per ancestry in our study population of 2655 singleton pregnancies: 1/142 African ancestry 2/1003 Hispanic, selfidentified as non-white 1/1220 European ancestry 0/265 Asian ancestry All 4 with available placenta blocks for CD123 IHC (RNAseq was not performed because RNAlater-preserved specimen was only available for 2 of the 4 cases) D

FIGURE 6